NDC 16571 is associated with quetiapine, an atypical antipsychotic medication. Quetiapine is primarily used to treat schizophrenia, bipolar disorder (manic and depressive episodes), and as an add-on treatment for major depressive disorder [1]. It works by affecting the activity of certain neurotransmitters in the brain, such as dopamine and serotonin [1].
What is quetiapine used for?
Quetiapine is prescribed for several mental health conditions. These include the treatment of schizophrenia in adults and adolescents 13 years and older [1]. It is also used to manage manic episodes associated with bipolar I disorder in adults and children 10 years and older, and depressive episodes associated with bipolar II disorder in adults and adolescents 10 years and older [1]. Additionally, quetiapine can be used as an adjunctive therapy for major depressive disorder in adults who have not responded adequately to other antidepressant treatments [1].
How does quetiapine work?
Quetiapine is classified as an atypical antipsychotic. It is believed to exert its therapeutic effects by altering the action of neurotransmitters in the brain, particularly dopamine and serotonin receptors [1]. By modulating these neurotransmitter systems, quetiapine can help to rebalance brain chemistry, which is often disrupted in conditions like schizophrenia and bipolar disorder.
What are the common side effects of quetiapine?
Like all medications, quetiapine can cause side effects. Some of the more common adverse effects reported include drowsiness, dizziness, dry mouth, constipation, weight gain, and blurred vision [1]. Patients may also experience increased cholesterol or triglyceride levels, or changes in blood sugar [1]. It is important for individuals taking quetiapine to discuss any side effects they experience with their healthcare provider.
When do quetiapine patents expire?
Information regarding specific patent expiry dates for quetiapine is typically found through specialized pharmaceutical patent databases. DrugPatentWatch.com provides resources that track patent status and expiry for many medications, including quetiapine [2]. The original patent for quetiapine (marketed as Seroquel) was granted in 1986 and expired in 2007 [3]. However, various secondary patents related to its formulation, manufacturing, or specific uses may have different expiry dates.
Who makes quetiapine?
The original developer of quetiapine was AstraZeneca, which marketed it under the brand name Seroquel [3]. Following the expiry of its primary patents, numerous generic pharmaceutical companies now manufacture and distribute quetiapine. The NDC (National Drug Code) number 16571 is associated with specific manufacturers and formulations of the drug.
Can generic versions of quetiapine be prescribed?
Yes, generic versions of quetiapine are widely available. Once the primary patents expire, other companies can produce and sell bioequivalent versions of the drug. These generic formulations contain the same active ingredient, quetiapine, and are approved by regulatory agencies to be safe and effective for the same uses as the brand-name product.
What are the risks associated with quetiapine use?
Quetiapine, like other antipsychotics, carries certain risks that patients and prescribers must consider. These include the potential for serious side effects such as tardive dyskinesia (involuntary movements), metabolic changes (weight gain, high blood sugar, high cholesterol), and neuroleptic malignant syndrome (a rare but life-threatening condition) [1]. It can also cause a significant drop in blood pressure when standing up, leading to dizziness or fainting, particularly when starting the medication or increasing the dose [1]. Quetiapine carries a boxed warning regarding increased mortality in elderly patients with dementia-related psychosis [1].
What is the difference between quetiapine and other antipsychotics?
Quetiapine is an atypical antipsychotic, which distinguishes it from older, typical antipsychotics. Atypical antipsychotics generally have a lower risk of causing extrapyramidal side effects (movement disorders) compared to typical ones. However, they may have a higher risk of metabolic side effects like weight gain and diabetes. Compared to other atypical antipsychotics, quetiapine has a unique receptor binding profile, which contributes to its specific efficacy and side effect profile. The choice of antipsychotic depends on the individual patient's condition, medical history, and tolerance to side effects.
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020651s051,021904s020,021475s037lbl.pdf
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/drugs/quetiapine